Medicamen Biotech Ltd

NSE
MEDICAMEQ •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Medicamen Biotech Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
46.78% Fall from 52W High
6.6
TTM PE Ratio
Above industry Median
59.7
Price to Book Ratio
Below industry Median
2.9
Dividend yield 1yr %
Below industry Median
0.2
TTM PEG Ratio
PEG TTM is negative
-1.7
RSI
RSI is mid-range
40.9
MFI
MFI oversold
23.9

Medicamen Biotech Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Medicamen Biotech Ltd shareholding Pattern

Promoter
43%
Foreign Institutions
0.1%
Domestic Institutions
1.2%
Public
55.8%
Promoter
43.2%
Foreign Institutions
0.1%
Domestic Institutions
1%
Public
55.7%
Promoter
43.2%
Foreign Institutions
0.2%
Domestic Institutions
0.7%
Public
55.9%
Promoter
43.2%
Foreign Institutions
0.2%
Domestic Institutions
0.2%
Public
56.4%
Promoter
43.2%
Foreign Institutions
0.2%
Domestic Institutions
0.2%
Public
56.4%
Promoter
43.2%
Foreign Institutions
0.2%
Domestic Institutions
0.2%
Public
56.4%

Medicamen Biotech Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
454.20
10Day EMA
459.80
12Day EMA
461.50
20Day EMA
466.40
26Day EMA
469.00
50Day EMA
474.80
100Day EMA
488.10
200Day EMA
530.50
5Day SMA
453.30
10Day SMA
462.70
20Day SMA
470.90
30Day SMA
470.50
50Day SMA
482.70
100Day SMA
467.00
150Day SMA
494.20
200Day SMA
527.60
Delivery & Volume
Resistance & Support
452.38
Pivot
Resistance
First Resistance
456.92
Second Resistance
464.08
Third Resistance
468.62
Support
First Support
445.22
Second support
440.68
Third Support
433.52
Relative Strength Index
40.88
Money Flow Index
23.87
MACD
-7.49
MACD Signal
-5.12
Average True Range
19.87
Average Directional Index
10.77
Rate of Change (21)
-0.39
Rate of Change (125)
-18.25
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Kilitch Drugs(I) Ltd.
576.39
175
470
Venus Remedies Ltd.
546.64
222
430
Vikram Thermo (India) Ltd.
-
-
-
Zim Laboratories Ltd.
-
-
-
Valiant Laboratories Ltd.
600.52
129.3
214.95
Accent Microcell Ltd.
-
-
-

Medicamen Biotech Ltd Company background

Founded in: 1993
Medicamen Biotech Ltd is a widely held, Globally Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. The company is engaged in manufacture and distribution of medicines. They manufacturer and supply the range of products such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non beta lactum) and ointment. The company has two manufacturing facilities namely, Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures NonBetalactum preparations including tablets, capsules, oral liquids and ointments creams.The company is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical Fraternity.Medicamen Biotech Ltd was incorporated on December 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange.In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitment.During the year 200607, the company added Analgesic and Anti bacterial, Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year, the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos.The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets, Capsules, oral liquids ointments with the production capacity of 4100 lakh Nos, 600 lakh Nos, 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.The Company launched the marketing division in Jan09, with 16 products in Delhi Uttrakhand regions. On September 16, 2015, M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company SPA 1 with Mr. Bal Kishan Gupta, Mr. Ashutosh Gupta, Ms. Ritu Gupta, Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal, Ms. Manju Bansal, Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 44,12,095 fully paidup Equity Shares of Rs.10/ each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company, which was completed in December, 2015 and the Acquirer became New Promoter of the Company.The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) 4,20,000 in 201920. OPAL, a wholly owned subsidiary of the Company, merged with the Company effective September 17, 2019. The Company has launched 12 Oncology products in domestic market effective from January, 2022.
Read More

Medicamen Biotech Ltd FAQs

Medicamen Biotech Ltd shares are currently priced at 449.75 on NSE and 449.7 on BSE as of 7/25/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Medicamen Biotech Ltd [MEDICAMEQ] share was -45.22. The Medicamen Biotech Ltd [MEDICAMEQ] share hit a 1-year low of Rs. 355.45 and a 1-year high of Rs. 845.

The market cap of Medicamen Biotech Ltd is Rs. 571.84 Cr. as of 7/25/2024 12:00:00 AM.

The PE ratios of Medicamen Biotech Ltd is 42.99 as of 7/25/2024 12:00:00 AM.

The PB ratios of Medicamen Biotech Ltd is 2.73 as of 7/25/2024 12:00:00 AM

You can easily buy Medicamen Biotech Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -